AI Engines For more Details: Perplexity Kagi Labs You
Diuretic Effect: Bumetanide belongs to the loop diuretic class of medications, which work by inhibiting the reabsorption of sodium and chloride in the kidneys, leading to increased urine production and elimination of excess fluid from the body. This helps reduce fluid buildup in tissues and organs, relieving symptoms of edema and reducing the workload on the heart.
Congestive Heart Failure: Bumetanide is commonly prescribed to manage fluid overload in individuals with congestive heart failure (CHF), a condition characterized by impaired heart function and fluid retention. By promoting diuresis, bumetanide helps alleviate symptoms such as shortness of breath, swelling (edema), and fatigue associated with CHF.
Hypertension: In some cases, bumetanide may be used as an adjunct therapy for the treatment of hypertension (high blood pressure), particularly when fluid retention contributes to elevated blood pressure levels. By reducing fluid volume, bumetanide can help lower blood pressure and improve cardiovascular function.
Liver Cirrhosis: Bumetanide may be prescribed to manage ascites, a common complication of liver cirrhosis characterized by abdominal fluid accumulation. By increasing urine output, bumetanide helps alleviate ascites and associated symptoms such as abdominal distension and discomfort.
Renal Disorders: Bumetanide is sometimes used to manage edema associated with renal disorders, including nephrotic syndrome and chronic kidney disease. By promoting diuresis, bumetanide helps reduce fluid retention and improve kidney function in these conditions.
Potassium and Electrolyte Imbalance: Bumetanide can cause electrolyte imbalances, particularly hypokalemia (low potassium levels), as it increases the excretion of sodium and potassium in the urine. Healthcare providers may monitor electrolyte levels regularly and prescribe potassium supplements or potassium-sparing diuretics to prevent or correct electrolyte disturbances.
Dehydration: Excessive diuresis induced by bumetanide can lead to dehydration, especially in vulnerable populations such as the elderly or individuals with preexisting dehydration risk factors. Patients are advised to maintain adequate fluid intake while taking bumetanide to prevent dehydration.
Ototoxicity: Rarely, bumetanide may cause ototoxicity, characterized by reversible or irreversible hearing loss or tinnitus (ringing in the ears). Patients experiencing symptoms of ototoxicity should discontinue bumetanide and seek medical evaluation.
Drug Interactions: Bumetanide may interact with other medications, including other diuretics, antihypertensive agents, and nonsteroidal anti-inflammatory drugs (NSAIDs), potentially leading to additive effects on blood pressure, electrolyte balance, and kidney function. Healthcare providers should review patients' medication regimens to minimize the risk of drug interactions.
Pregnancy and Lactation: Bumetanide should be used with caution during pregnancy and breastfeeding, as its safety profile in these populations is not well-established. Healthcare providers may weigh the potential benefits against the risks when prescribing bumetanide to pregnant or breastfeeding individuals.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Bacteroides uniformis | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0 | 0 | |
Acne | 0 | 0 | |
ADHD | 0.6 | 0.6 | |
Allergic Rhinitis (Hay Fever) | 0.1 | 0 | 0 |
Allergies | 0.3 | 0.6 | -1 |
Allergy to milk products | 0.4 | 0 | 0 |
Alopecia (Hair Loss) | 0.2 | 0.2 | |
Alzheimer's disease | 0.6 | 1.1 | -0.83 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0 | 0.3 | 0 |
Ankylosing spondylitis | 0.3 | 0.3 | 0 |
Anorexia Nervosa | 0.6 | -0.6 | |
Antiphospholipid syndrome (APS) | 0.1 | 0 | 0 |
Asthma | 0.1 | 0.1 | 0 |
Atherosclerosis | 0.3 | 0 | 0 |
Atrial fibrillation | 0.7 | 0.1 | 6 |
Autism | 0.8 | 0.9 | -0.13 |
Barrett esophagus cancer | 0.1 | -0.1 | |
Biofilm | 0.1 | 0.1 | |
Bipolar Disorder | 0.4 | 0.3 | 0.33 |
Brain Trauma | 0 | 0.1 | 0 |
Cancer (General) | 0.3 | -0.3 | |
Carcinoma | 0.6 | 0.5 | 0.2 |
Celiac Disease | 0.1 | 0.6 | -5 |
Cerebral Palsy | 0.1 | 0.5 | -4 |
Chronic Fatigue Syndrome | 1.5 | 0.8 | 0.88 |
Chronic Kidney Disease | 0.2 | 0.2 | 0 |
Chronic Lyme | 0.1 | -0.1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.4 | |
Chronic Urticaria (Hives) | 0.1 | 0.1 | |
Coagulation / Micro clot triggering bacteria | 0.1 | 0.5 | -4 |
Colorectal Cancer | 0.5 | 0.1 | 4 |
Constipation | 0.1 | 0.2 | -1 |
Coronary artery disease | 0.4 | 0.2 | 1 |
COVID-19 | 1.2 | 2.2 | -0.83 |
Crohn's Disease | 0.8 | 0.7 | 0.14 |
cystic fibrosis | 0.1 | -0.1 | |
deep vein thrombosis | 0.4 | -0.4 | |
Depression | 0.9 | 1.1 | -0.22 |
Dermatomyositis | 0.1 | 0 | 0 |
Eczema | 0.3 | -0.3 | |
Endometriosis | 0.3 | 0.3 | 0 |
Epilepsy | 0.3 | 0.2 | 0.5 |
Fibromyalgia | 0.2 | 0.3 | -0.5 |
Functional constipation / chronic idiopathic constipation | 0.4 | 0.3 | 0.33 |
gallstone disease (gsd) | 0.5 | 0 | 0 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0 | 0.4 | 0 |
Generalized anxiety disorder | 0.2 | 0.1 | 1 |
giant cell arteritis | 0 | 0 | |
Glioblastoma | 0.1 | -0.1 | |
Graves' disease | 0.1 | 0.2 | -1 |
Halitosis | 0.1 | 0.1 | 0 |
Hashimoto's thyroiditis | 0.4 | 0.1 | 3 |
Hidradenitis Suppurativa | 0.1 | 0.1 | |
High Histamine/low DAO | 0.1 | 0.3 | -2 |
hypercholesterolemia (High Cholesterol) | 0 | 0 | |
hyperglycemia | 0.2 | -0.2 | |
Hyperlipidemia (High Blood Fats) | 0 | 0 | |
hypersomnia | 0.2 | -0.2 | |
hypertension (High Blood Pressure | 0.4 | 0.4 | 0 |
Hypothyroidism | 0.2 | -0.2 | |
Hypoxia | 0.1 | 0.1 | |
IgA nephropathy (IgAN) | 0.3 | -0.3 | |
Inflammatory Bowel Disease | 0.3 | 1.4 | -3.67 |
Insomnia | 0.3 | 0.1 | 2 |
Intelligence | 0.2 | 0.2 | |
Intracranial aneurysms | 0.5 | 0.5 | |
Irritable Bowel Syndrome | 0.4 | 0.3 | 0.33 |
Liver Cirrhosis | 0.7 | 0.5 | 0.4 |
Long COVID | 0.4 | 1.6 | -3 |
Lung Cancer | 0.4 | -0.4 | |
Mast Cell Issues / mastitis | 0.1 | 0.3 | -2 |
ME/CFS with IBS | 0.1 | 0.4 | -3 |
ME/CFS without IBS | 0.1 | 0.1 | 0 |
Menopause | 0 | 0 | |
Metabolic Syndrome | 0.7 | 0.9 | -0.29 |
Mood Disorders | 1.3 | 1.1 | 0.18 |
multiple chemical sensitivity [MCS] | 0.3 | 0.2 | 0.5 |
Multiple Sclerosis | 0.9 | 0.7 | 0.29 |
Multiple system atrophy (MSA) | 0.1 | 0.5 | -4 |
neuropathic pain | 0.1 | -0.1 | |
Neuropathy (all types) | 0.2 | 0.2 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.3 | 1.1 | -2.67 |
NonCeliac Gluten Sensitivity | 0.2 | 0.1 | 1 |
Obesity | 0.8 | 0.9 | -0.13 |
obsessive-compulsive disorder | 1.2 | 0.5 | 1.4 |
Osteoarthritis | 0.2 | 0.3 | -0.5 |
Osteoporosis | 0.4 | 0.2 | 1 |
pancreatic cancer | 0.1 | 0.1 | |
Parkinson's Disease | 0.8 | 0.8 | 0 |
Polycystic ovary syndrome | 0.6 | 0.6 | 0 |
Postural orthostatic tachycardia syndrome | 0 | 0 | 0 |
Premenstrual dysphoric disorder | 0.2 | 0.2 | |
primary biliary cholangitis | 0.2 | -0.2 | |
Psoriasis | 0.6 | 0.1 | 5 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.6 | 0.1 | 5 |
Rosacea | 0.5 | 0 | 0 |
Schizophrenia | 0.8 | 0.5 | 0.6 |
scoliosis | 0.3 | -0.3 | |
Sjögren syndrome | 0.2 | 0.6 | -2 |
Sleep Apnea | 0.5 | 0.2 | 1.5 |
Slow gastric motility / Gastroparesis | 0.3 | 0 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.1 | |
Stress / posttraumatic stress disorder | 0.1 | 0.1 | 0 |
Systemic Lupus Erythematosus | 0.3 | 0.5 | -0.67 |
Tic Disorder | 0.3 | 0 | 0 |
Tourette syndrome | 0.1 | -0.1 | |
Type 1 Diabetes | 0.6 | 0.2 | 2 |
Type 2 Diabetes | 0.6 | 0.9 | -0.5 |
Ulcerative colitis | 0.5 | 0.4 | 0.25 |
Unhealthy Ageing | 0.4 | 0.2 | 1 |
Vitiligo | 0.4 | 0.1 | 3 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [98.80.143 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [98.80.143 ]